Prognostic role of intratumoral IL-17A expression by immunohistochemistry in solid tumors: a meta-analysis

Supplementary Materials



Supplementary Figure 1: Forest plots describing HR of the association between intratumoral IL-17A and OS in solid tumors.



Supplementary Figure 2: Forest plots describing HR of the association between intratumoral IL-17A and DFS in solid tumors.



Supplementary Figure 3: Plots describing the influence of individual studies on the OR for OS at 1-year, 3-year, 5-year.

Supplementary Table 1: Characteristics of the included studies for OR analysis of clinicopathological features

Study	Year	Tumor type	No. of Patients	Cut off for high expression	IL-17A High expression (%)	T category (T1+T2 / T3+T4)	N category (Positive / Negative)	M category (M0/M1)	Tumor stage	I + II / III + IV	Tumor Differentiation (Well-moderate/poor)
Chen WC, et al. [35]	2013	Breast cancer	207	positive cells > 90/HPF	37 (17.9)	H: (23/14); L: (127/43)	H: (11/26); L: (74/96)	NR	I–III	H: (23/14); L: (114/56)	H:(24/13); L: (121/49)
Chen X, et al. [21]	2010	Non-small cell lung cancer	52	positive cells >5%/HPF	25 (48.1)	NR	NR	NR	I–III	H: (12/13); L: (21/6)	H:(3/22); L: (7/20)
Chen JG, et al. [25]	2011	Gastric cancer	192	density of positive cells > 2.5/HPF	100 (52.1)	H: (21/79); L: (20/72)	H: (72/28); L: (69/23)	NR	I–IV	H: (58/42); L: (65/37)	H:(25/75); L: (21/71)
Liu JK, et al. [29]	2011	Colorectal cancer	52	positive cells > 5%	26 (50.0)	NR	NR	NR	III	NR	H:(16/10); L: (18/8)
Zhang GQ, et al. [35]	2012	Non-small cell lung cancer	102	intensity of staining	71 (69.6)	NR	NR	NR	I–III	H: (44/28); L: (25/5)	H:(44/30); L: (15/13)
Lin Y, et al. [23]	2014	Colorectal cancer	78	score ≥ 3	67 (85.9)	NR	H: (39/28); L: (8/3)	H: (49/18); L: (6/5)	I–IV	H: (28/39); L: (1/10)	H:(52/4); L: (4/4)
Gu FM, et al. [32]	2011	Hepatocellular carcinoma	323	density of positive cells	162 (50.2)	NR	NR	NR	I–III	NR	H:(126/36);L: (129/32)
Zhang Y, et al. [33]	2013	Gallbladder carcinoma	104	positive cells/ HPF	54 (51.9)	H:(18/36); L:(24/26)	H:(12/42); L:(4/46)	H: (47/7); L: (45/5)	I–IV	H: (16/38); L: (26/24)	H:(35/19); L: (35/15)
Wang B, et al. [24]	2013	Esophageal squamous cell cancer	215	density of positive cells > 10%	106 (49.3)	H:(49/57); L:(31/76)	H:(41/65); L:(56/53)	NR	I–IV	NR	H:(81/25); L: (83/26)

T: primary tumor; N: lymph node; M: metastasis; H: high; L: low; NR: not reported; HPF: high-power field.

Supplementary Table 2: Specific criteria of Newcastle-Ottawa Scale (NOS)

NOTE: Identify 'high' quality choices with a 'star' (one 'star' means 1 score); A maximum of one 'star' for each item within the *'Selection'* and *'Outcome'* categories; maximum of two 'stars' for *'Comparability'*. Using the tool, each study is judged on eight items, categorized into three groups: the 'selection' of the study groups; the 'comparability' of the groups; and the ascertainment of the outcome of interest for cohort studies. Stars awarded for each quality item serve as a quick visual assessment. Stars are awarded such that the highest quality studies are awarded up to nine stars.
1, Selection (4)
(1), Representativeness of the exposed cohort a) truly representative of the average ____ (describe) in the community ★ b) somewhat representative of the average ____ in the community ★ c) selected group of users eg nurses, volunteers d) no description of the derivation of the cohort (2), Selection of the non exposed cohort a) drawn from the same community as the exposed cohort ★ b) drawn from a different source c) no description of the derivation of the non exposed cohort (3), Ascertainment of exposure to implants a) secure record (eg surgical records) ★ b) structured interview ★ c) written self report d) no description (4), Demonstration that outcome of interest was not present at start of study a) yes ★ b) no
2, Comparability (1) (1), Comparability of cohorts on the basis of the design or analysis a) study controls for _____ (select the most important factor) ★ b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) ★
3, Outcome (3)
(1), Assessment of outcome a) independent blind assessment ★ b) record linkage ★ c) self report d) no description (2), Was follow up long enough for outcomes to occur a) yes (select an adequate follow up period for outcome of interest) ★ b) no (3), Adequacy of follow up of cohorts a) complete follow up - all subjects accounted for ★ b) subjects lost to follow up unlikely to introduce bias - small number lost - > ___ % (select an adequate %) follow up, or description of those lost) ★ c) follow up rate < ___% (select an adequate %) and no description of those lost d) no statement

Supplementary Table 3: Study quality assessment according to the Newcastle–Ottawa Scale (NOS)

Study	Year	Selection				Comparability		Outcome			Quality Score (NOS)
		(1)	(2)	(3)	(4)	(1) - a	(1) - b	(1)	(2)	(3)	
Chen WC, et al. [35]	2013	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	8
Chen X, et al. [21]	2010	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	7
Chen JG, et al. [25]	2011	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	8
Cui XL, et al. [26]	2013	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	7
Gu FM, et al. [28]	2012	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	7
Lan CY, et al. [27]	2013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	8
Liao R, et al. [18]	2013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	7
Liu JK, et al. [29]	2011	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	7
Lv L, et al. [22]	2011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	8
Zhang JP, et al. [19]	2009	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	7
Zhang GQ, et al. [30]	2012	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	7
Lin Y, et al. [23]	2014	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	8
Liu XS, et al. [31]	2014	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	8
Gu FM, et al. [32]	2011	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Li J, et al. [20]	2011	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	7
Punt S, et al. [36]	2015	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Zhang Y, et al. [33]	2013	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
He SB, et al. [34]	2011	Yes	Yes	No	Yes	No	Yes	Yes	No	Yes	6
Wang B, et al. [24]	2013	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	7
Yu Q, et al. [37]	2014	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	6
Tosolini M, et al. [38]	2011	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	6